Difference between revisions of "Part:BBa K1041003:Design"

 
 
Line 1: Line 1:
−
 
 
__NOTOC__
 
__NOTOC__
 
<partinfo>BBa_K1041003 short</partinfo>
 
<partinfo>BBa_K1041003 short</partinfo>
Line 7: Line 6:
  
 
===Design Notes===
 
===Design Notes===
−
Restriction digest
+
Team NRP-UEA_Norwich 2013 designed this part using biobricks BBa_K1041000 and BBa_K1041001. These biobricks both contain an Nde1 site after their promoter sequence, enabling a restriction digest to be performed. The Neomycin resistance coding gene would be excised from BBa_K1041001 and ligated downstream of the promoter of BBa_K1041000 to create a new biobrick. When prepared, the resulting biobrick should provide resistance to neomycin (kanamycin) when transformed into any strain of ''E. coli''.
  
  
Line 13: Line 12:
 
===Source===
 
===Source===
  
−
Bba_J04450  
+
Bba_K1041000 and Bba_K10401001
 +
Original source: Bba_J04450  
  
 
===References===
 
===References===

Latest revision as of 22:34, 4 October 2013

Neomycin Resistance Reporter Gene


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 855
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal SapI.rc site found at 704
    Illegal SapI.rc site found at 914


Design Notes

Team NRP-UEA_Norwich 2013 designed this part using biobricks BBa_K1041000 and BBa_K1041001. These biobricks both contain an Nde1 site after their promoter sequence, enabling a restriction digest to be performed. The Neomycin resistance coding gene would be excised from BBa_K1041001 and ligated downstream of the promoter of BBa_K1041000 to create a new biobrick. When prepared, the resulting biobrick should provide resistance to neomycin (kanamycin) when transformed into any strain of E. coli.


Source

Bba_K1041000 and Bba_K10401001 Original source: Bba_J04450

References